Composite medicament stent for inhibiting cardiovascular restenosis and preparation method

Abstract

The invention relates to a composite medicament stent for inhibiting cardiovascular restenosis and a preparation method. The stent is prepared by performing laser cutting on a metal tube; the surface of the stent is corroded by electrochemical acid solution so as to form nanopores; the surface of a main body is coated with a nondegradable bioactive coating with thickness of 10 to 50 microns; a degradable biocompatible polymer medicament coating with thickness of 10 to 100 microns are coated outside the nondegradable bioactive coating; the nondegradable bioactive coating is prepared by mixing a nondegradable biocompatible high polymer, active biological components, an organic solvent and the like to form solution and spraying and drying the solution and the like; and the medicament coating is prepared by mixing a degradable biocompatible high polymer, anti-restenosis medicament ingredients, an organic solvent and the like to form solution and spraying and drying the solution and the like. The composite medicament stent has the characteristics of slow medicament release and capability of effectively reducing restenosis and thrombosis at the later stage of stent implantation.

Description

(1) Technical field [0001] The invention belongs to the field of medical equipment, and relates to a composite drug stent for inhibiting cardiovascular restenosis for minimally invasive interventional treatment of cardiovascular diseases and a preparation method thereof. (2) Background technology [0002] Coronary atherosclerotic heart disease is one of the important causes of death from cardiovascular diseases, and it is a common disease that seriously threatens human life and health. With the improvement of human living standards and the aging process of the population, the incidence of this disease is on the rise. In 1987, Sigwart and others used intravascular metal stents for the first time to treat coronary artery stenosis, and received ideal results. Since then, they have created a new way to treat various vascular blockages and stenosis diseases. At present, percutaneous coronary angioplasty (PTCA) has become a common method for clinical treatment of coronary heart d...

AI Technical Summary

Problems solved by technology

[0004] At present, the use of drug-coated stents has greatly reduced the occurrence of restenosis in stents. Although drug-eluting stents can effectively inhibit the proliferation of smooth muscle cells, they have little effect on the capture of vascular endothelial progenitor cells and the repair of vascular endothelium. 20% to 40% of patients still have late thrombosis

Images